Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AST SpaceMobile Inc (ASTS) vs Viatris Inc (VTRS) Price & Performance

AST SpaceMobile IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

AST SpaceMobile Inc vs Viatris Inc — how do they compare? AST SpaceMobile Inc trades at $71.58 (market cap $20.54B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: AST SpaceMobile Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.95% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.

ASTSVTRS
Market Cap
$20.54B$18.69B
Sector
MediaHealth
52-Week High
$133.09$17.86
52-Week Low
$36.91$9.49
Enterprise Value
$21.25B$30.81B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AST SpaceMobile Inc

AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.

Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.

Viatris Inc

Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.

While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AST SpaceMobile Inc

AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.

Read more on ASTS

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS